Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Interest of GEP-based Derived Histone Acetylation Score to Identify Myeloma Patients Who Could Benefit From Treatment With HDAC Inhibitor

NCT03515915 is registered in ClinicalTrials.gov with University Hospital, Montpellier as lead sponsor.

NCT NCT03515915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03515915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Interest of GEP-based Derived Histone Acetylation Score to Identify Myeloma Patients Who Could Benefit From Treatment With HDAC Inhibitor
Lead sponsor
University Hospital, Montpellier
Phase
Observational
Overall status
Unknown status
Start date
April 23, 2018
Completion date
December 31, 2019
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients with recurrent or refractory multiple myeloma